Current and emerging prospects in the psoriatic treatment

Int Immunopharmacol. 2023 Jul:120:110331. doi: 10.1016/j.intimp.2023.110331. Epub 2023 May 19.

Abstract

Psoriasis is an autoimmune chronic disorder that causes inflammation and a scaly epidermis. The exact pathogenesis of the disease is not known yet. According to the studies, psoriasis is considered an immune-mediated disease. Until now it is believed that genetic and environmental factors are responsible for the disease. There are many comorbidities associated with psoriasis which increases difficulties as patients in some cases get addicted to drugs, alcohol, and smoking which reduces their quality of life. The patient may face social ignorance or suicidal thoughts which may arise in the patient's mind. Due to the undefined trigger of the disease, the treatment is not fully established but by considering the severe impact of the disease researchers are focusing on novel approaches for successful treatment. which has succeeded to a large extent. Here we review pathogenesis, problems faced by psoriatic patients, the need for the development of new treatments over conventional therapies, and the history of psoriatic treatments. We thoroughly focus on emerging treatments like biologics, biosimilars, and small molecules which are now showing more efficacy and safety than conventional treatments. Also, this review article discusses novel approaches which are now in research such as drug repurposing, treatment by stimulation of the vagus nerve, regulation of microbiota, and autophagy for improving disease conditions.

Keywords: Biologics; Biosimilars; Novel treatment approaches; Psoriasis; Small molecules.

Publication types

  • Review

MeSH terms

  • Biosimilar Pharmaceuticals* / therapeutic use
  • Comorbidity
  • Humans
  • Psoriasis* / drug therapy
  • Quality of Life
  • Skin / pathology

Substances

  • Biosimilar Pharmaceuticals